Skip to main content

Table 2 Parasite positivity rate (PPR) for three different ACTs

From: Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data

 

AL

AS-AQc

DP

Overall

Day 1

    

PPR (%)a

59.3 % (4,721/7,966) (95 % CI: 52.2–66.3)

60.3 % (3,463/5,746) (95 % CI: 54.7–65.8)

59.8 % (1,915/3,204) (95 % CI: 50.3–69.2)

59.7 % (10,099/16,916) (95 % CI: 54.5–64.9)

Number of study sitesb

81

52

25

158

Median PPR (IQR; range)b

61.8 % (35.5–79.1; 0–97.6)

58.8 % (47.1–77.0; 0.0–96.3)

53.8 % (32.4–69.4; 18.3–93.0)

57.9 % (36.1–77.0; 0.0–97.6)

Day 2

    

PPR (%)a

5.9 % (729/12,255)

7.2 % (784/10,821)

7.7 % (340/4,420)

6.7 % (1,853/27,496)

Number of study sitesb

100

79

36

215

Median PPR (IQR; range)b

2.9 (1–8.3; 0.0–42.4)

5.6 % (1.5–12.3; 0.0–88.1)

3.9 % (0.4–6.7; 0.0–39.1)

3.3 % (1.2–10.2; 0.0–88.1)

Day 3

    

PPR (%)a

0.6 % (76/13,004)

1.3 % (143/11,142)

0.8 % (34/4,434)

0.9 % (253/28,580)

Number of study sitesb

105

84

36

225

Median PPR (IQR; range)b

0.0 % (0.0–0.9; 0.0–7.8)

0.3 % (0.0–1.6; 0.0–30.7)

0.0 % (0.0–0.5; 0.0–7.7)

0.0 % (0.0–0.7;0.0–30.7)

  1. aThe PPR was computed using all available data and associated 95 % confidence interval was adjusted for within site correlation; bonly sites with the number of patients >25 were considered; cPPRs (95 % CI) on days 1, 2 and 3 were 62.3 % (52.4–72.3), 4.9 % (2.5–7.3) and 0.5 % (0.1–0.9) for ASAQ–FDC (from 32 sites); 58.4 % (50.2–66.6), 8.7 % (6.3–11.2) and 1.7 % (1.0–2.4) for ASAQ-loose NFDC (from 43 sites); and 58.9 % (52.6–65.3), 10.6 % (0–21.3) and 2.4 % (0–5.7) for ASAQ-coblistered NFDC (from 9 sites), respectively. Detailed information of PPR is presented in Additional file 4. ACT, artemisinin-based combination therapy; AL, artemether-lumefantrine; AS-AQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; PPR, parasite positivity rate